Alembic Pharmaceuticals reported its Q4 FY26 results with steady revenue growth and strong improvement in net profit on a year-on-year basis.
The company’s revenue from operations stood at ₹1,847.72 crore in the March 2026 quarter, up 4.4% compared to ₹1,769.64 crore reported in the corresponding quarter last year. Total income increased 5.0% YoY to ₹1,873.22 crore from ₹1,783.83 crore.
Total expenses during the quarter rose 8.8% YoY to ₹1,730.94 crore against ₹1,591.22 crore in Q4 FY25. Employee benefit expenses climbed 11.5% to ₹438.91 crore, while depreciation and amortisation expenses surged 28.4% YoY to ₹88.59 crore.
Profit before tax declined 38.2% to ₹118.62 crore in Q4 FY26 versus ₹191.95 crore in the year-ago period, impacted by higher expenses and exceptional items.
However, net profit for the quarter rose 29.2% YoY to ₹202.70 crore compared to ₹156.89 crore reported in Q4 FY25.
For the full financial year FY26, Alembic Pharmaceuticals reported revenue from operations of ₹7,344.90 crore, registering a growth of 10.1% over ₹6,672.08 crore in FY25. Total income rose 10.2% YoY to ₹7,399.31 crore.
Annual profit before tax slipped 1.9% to ₹693.95 crore from ₹707.18 crore in the previous financial year. Net profit for FY26 increased 15.7% to ₹674.77 crore compared to ₹583.42 crore reported in FY25.